Market Overview

Caladrius Shares Extend Rally After FDA Grants Special Status To Cell Therapy

Caladrius Shares Extend Rally After FDA Grants Special Status To Cell Therapy

Caladrius Biosciences Inc (NASDAQ: CLBS) shares were trading sharply higher for a second straight session Wednesday after the FDA granted a special status for its CD34+ cell therapy.

What Happened

Caladrius Biosciences announced Tuesday ahead of the market open that the FDA granted regenerative medicine advanced therapy, or RMAT, designation to its late-stage CD34+ cell therapy program for treating refractory angina.

Refractory angina is chronic symptomatic coronary artery disease, with symptoms manifesting as chest pain, shortness of breath and extreme fatigue.

Why It's Important

The designation is usually accorded to therapies intended to treat serious conditions that have the potential to address unmet medical needs.

The designation expedites drug development and the review of marketing applications with increased meeting opportunities; early interactions to discuss potential or surrogate or intermediate endpoints; shortened BLA review times; and the potential of accelerated approval.

What's Next

The CD34+ program, which Caladrius acquired from Shire PLC (ADR) (NASDAQ: SHPG) in March 2018, vests the former with the responsibility of manufacturing, preclinical and Phase 1, 2 and 3 clinical study data for the CD34 cell therapy as a treatment for no-option refractory angina, along with corresponding regulatory filings.

Following a 67.34 percent jump to $6.61 Tuesday, Caladrius shares were trading up 41.45 percent to $9.35 at the time of publication Wednesday morning. 

Related Links:

Benzinga's Daily Biotech Pulse: Sarepta's DMD Gene Therapy, Anik

The Week Ahead In Biotech: Conferences, Clinical Trials And IPOs

Posted-In: Biotech News FDA Movers Trading Ideas Best of Benzinga


Related Articles (SHPG + CLBS)

View Comments and Join the Discussion!

State Street Launches ETF Ahead Of Communication Services Sector Debut

The Original Dow Jones Industrial Average: Where Are They Now?